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LETTER TO THE EDITOR

Will “social distancing” lead to future “research distancing”:
A reflection on COVID-19 impacts on Alzheimer’s disease
research
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Abstract
Coronavirus disease 19 (COVID-19) has dramatically altered everyday life, including
the field of Alzheimer’s disease (AD) research. This perspective article explores some
of the ways in which COVID-19 has already impacted the field, anticipates some of
the long-lasting effects, and explores strategies for addressing current and future
needs. Areas of impact include study integrity, regulatory and industry issues, and
participant engagement. Proposed strategies for addressing these challenges include
analytic methods to deal with large degrees of missing data and development of
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patient-centered, user-friendly, remote data collection tools and assessments. We also
highlight the importance of maintaining participant well-being as a first and constant
priority.
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The coronavirus disease 19 (COVID-19) pandemic has disrupted

1

STUDY INTEGRITY

everyday life around the globe.1 For those of us working in the area of
Alzheimer’s disease (AD) prevention and treatment, it is important to

The immediate impact of COVID-19 includes analytic challenges with

take stock of the immediate impact, anticipate some ongoing effects,

ongoing studies that, due to requirements for social distancing, will

respond to current needs, and anticipate future challenges. This letter

now have inconsistent adherence to protocols as designed with visit

is focused on the impact of COVID-19 on clinical research in popula-

schedules and medication and intervention adherence all more fluid

tions of individuals at risk for or with dementia. Although several of

than in ideal circumstances.3 Addressing this challenge will require

these challenge areas were addressed briefly in a recent Alzheimer’s &

skilled statisticians using available, and perhaps novel, analytic meth-

Dementia editorial, we expand upon them here and offer thoughts for a

ods to ensure that we do not incorrectly conclude that a new treatment

path forward.2

is ineffective due to midstream pauses and interruption of drug dosing.
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Although we are all still reeling from the rapid onset of this crisis, we
also need to consider the possibility that higher than anticipated study

RESEARCH IN CONTEXT

attrition may lead to failed trials.
1. Systematic Review: Due to the recent and rapid emergence of severe acute respiratory syndrome coronavirus

2

2 (SARS-CoV-2), the virus that causes coronavirus dis-

REGULATORY AND INDUSTRY ISSUES

ease 19 (COVID-19) and its impact, this perspective piece
incorporates the expert opinions of the authors and their

It remains unclear, but of critical importance, how will regulatory agen-

careful consideration of the areas of Alzheimer’s disease

cies consider the data stemming from AD trials interrupted by COVID-

(AD) research likely to be affected now and moving for-

19. In the United States, the U.S. Food and Drug Administration (FDA)

ward, as well as ways in which the field can adapt. A brief

has issued statements of assurance that they understand the need

PubMed review for relevant articles paralleled this effort.

for study interruptions and protocol deviations, but how they will

2. Interpretation: This perspective piece highlights impor-

resolve the impact of such study conduct on future regulatory deci-

tant considerations and a path forward to help transform

sions remains unknown. Given these considerations, industry sponsors

the challenges that COVID-19 brings to AD research into

are currently weighing the cost/risk/benefit ratios of continuing ongo-

constructive change.

ing studies or simply halting trials altogether and beginning anew once

3. Future Directions: Moving forward it will be important

the crisis has abated.

to evaluate how proposed changes affect participant and
research outcomes and whether they can make the field
more resilient to future challenges.

3
IMPACT ON CURRENT PARTICIPANTS AND
PROSPECTIVE RECRUITMENT
We have encountered mixed feelings among participants; some are voluntarily pulling back from their research engagement in the face of

data collection has been clearly demonstrated, we anticipate an

the immediate threat the COVID-19 crisis posits to their health and

increased investment in the development of remote tools and assess-

well-being and others wish to push on as they understand AD’s pro-

ments that will enable gathering of clinical and neuropsychological

found and ongoing impact. Today’s social distancing requirements may

data from the participant’s home. This is a welcome move toward

have long-lasting effects, including lingering apprehension about social

increased participant-centeredness. This transition, however, will

contact and a shift from altruistic research motivations to choices to

be accompanied by additional challenges to ensure that we do not

remain more isolated to protect one’s own health. The limited pool of

exacerbate existing health disparities by leaving those without access

participants willing to engage in AD research may become even more

to technology, which may be required for remote monitoring activities,

limited in the future if heavy demands are placed on research activi-

behind.

ties within centers that may be perceived in the future as hotspots for
contagion. Maximal impacts for such societal change would be seen in
the area of invasive study procedures and biomarker collections, which

5

CONCLUSION

are critical for the conduct of state-of-the-art clinical trial research
in the area of preclinical, prodromal, and even fulminant AD. Further-

We believe the field can rise to meet the current challenges, transform-

more, with morbidity, mortality, and economic hardship disproportion-

ing the need for social distancing into an impetus for positive change.

ately affecting those who are already disadvantaged, we anticipate

These potential beneficial changes in trial design, statistical method-

increased challenges engaging diverse and underrepresented individu-

ologies to address even large swaths of missing data, changes in regula-

als in research, raising concerns for generalizability.4

These challenges

tory rules and oversight, and the development of new tools for remote

and the need for innovation will coexist within an uncertain funding

assessment of cognition and decline are critical priorities for the field.

landscape as we deal with the global economic fallout from this pan-

These areas provide a real opportunity for constructive change in the

demic.

face of what is otherwise a devastating crisis.
While responding to and anticipating these challenges, we need to
keep our participants at the forefront of our thoughts. Demonstrating

4
CHANGES WE HOPE TO SEE IN THE CLINICAL
TRIAL LANDSCAPE

that protecting participants is a priority will go a long way to building
and maintaining trust in research. In contrast, if we put research needs
above participant health we will have significant distrust to overcome

After we move past the most acute period of COVID-19, the effects

in the future. Our efforts today can dramatically improve the clinical

on AD clinical research will persist. Because the need for remote

trial landscape as we move forward.
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